Craig R. Stumpf, Ph.D.
Affiliations: | University of Wisconsin, Madison, Madison, WI |
Google:
"Craig Stumpf"Mean distance: 18.94 (cluster 32) | S | N | B | C | P |
Parents
Sign in to add mentor| Marvin Wickens | grad student | 2008 | UW Madison | |
| (Diverse PUFs with distinct PBEs: Characterization of PUF-RNA binding specificity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Parker GS, Toth JI, Fish S, et al. (2024) Discovery of Monovalent Direct Degraders of BRD4 that Act via the Recruitment of DCAF11. Molecular Cancer Therapeutics. OF1-OF13 |
| Parker GS, Toth JI, Fish S, et al. (2024) Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11. Molecular Cancer Therapeutics |
| Shukla T, de la Peña JB, Perish JM, et al. (2020) A Highly Selective MNK Inhibitor Rescues Deficits Associated with Fragile X Syndrome in Mice. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics |
| Xu Y, Poggio M, Jin HY, et al. (2019) Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine |
| Young NP, Stumpf CR, Chen J, et al. (2019) Abstract 4343: A focused CRISPR screen to identify synthetic lethal interactions with the novel eIF4A inhibitor eFT226 in KRAS driven NSCLC Cancer Research. 79: 4343-4343 |
| Stumpf CR, Goel VK, Sharma RK, et al. (2019) Abstract 4142: Physical and functional interactions between MNK and mTOR signaling regulate the activation and differentiation of T cells Cancer Research. 79: 4142-4142 |
| Chiang GG, Parker GS, Hung IN, et al. (2019) Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E Cancer Research. 79: 1302-1302 |
| Thompson PA, Young NP, Stumpf CR, et al. (2019) Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers Molecular Cancer Therapeutics. 18 |
| Reich SH, Sprengeler PA, Chiang GG, et al. (2018) Structure-based Design of Pyridone-aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition. Journal of Medicinal Chemistry |
| Stumpf CR, Chen J, Goel VK, et al. (2018) Abstract 3855: Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response Cancer Research. 78: 3855-3855 |